Stakeholders clashed Friday (March 27) at a public meeting over FDA's proposed rule that would require generic drug makers update their labels independently as they discover new safety information. Supporters of the agency's proposal said generic manufacturers should be held to the same standards as their brand-name counterparts, and opponents said only FDA has the authority to make changes and different labels will confuse providers and patients. The Generic Pharmaceutical Association (GPhA) and the Pharmaceutical Researchers and Manufacturers of America...